MA32969B1 - Compositions pharmaceutiques presentant de remarquables performances et entrainant une excellente adhesion du patient a son traitement - Google Patents
Compositions pharmaceutiques presentant de remarquables performances et entrainant une excellente adhesion du patient a son traitementInfo
- Publication number
- MA32969B1 MA32969B1 MA34019A MA34019A MA32969B1 MA 32969 B1 MA32969 B1 MA 32969B1 MA 34019 A MA34019 A MA 34019A MA 34019 A MA34019 A MA 34019A MA 32969 B1 MA32969 B1 MA 32969B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- pharmaceutical compositions
- remarkable performance
- excellent patient
- patient membership
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne de nouvelles formulations de l'ester (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-fluoro-2-isobutyryloxyméthyl-4-méthyl-tétrahydro-furan-3-ylique de l'acide isobutyrique et de l'hydroxypropylcellulose, caractérisées par une masse volumique apparente élevée, par une faible taille des particules permettant une meilleure compression et une fluidité améliorée, par une bonne compression et par des profils de dissolution rapides.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14599909P | 2009-01-21 | 2009-01-21 | |
PCT/EP2010/050182 WO2010084041A2 (fr) | 2009-01-21 | 2010-01-11 | Compositions pharmaceutiques présentant de remarquables performances et entraînant une excellente adhésion du patient à son traitement |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32969B1 true MA32969B1 (fr) | 2012-01-02 |
Family
ID=42026386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34019A MA32969B1 (fr) | 2009-01-21 | 2010-01-11 | Compositions pharmaceutiques presentant de remarquables performances et entrainant une excellente adhesion du patient a son traitement |
Country Status (28)
Country | Link |
---|---|
US (1) | US8222230B2 (fr) |
EP (1) | EP2389164B1 (fr) |
JP (1) | JP5415561B2 (fr) |
KR (1) | KR101331723B1 (fr) |
CN (1) | CN102292075B (fr) |
AR (1) | AR075037A1 (fr) |
AU (1) | AU2010206224B2 (fr) |
BR (1) | BRPI1006924A2 (fr) |
CA (1) | CA2748895C (fr) |
CL (1) | CL2011001764A1 (fr) |
CO (1) | CO6440558A2 (fr) |
DK (1) | DK2389164T3 (fr) |
EC (1) | ECSP11011191A (fr) |
ES (1) | ES2513415T3 (fr) |
HK (1) | HK1164742A1 (fr) |
IL (1) | IL213804A0 (fr) |
MA (1) | MA32969B1 (fr) |
MX (1) | MX2011007771A (fr) |
NZ (1) | NZ593795A (fr) |
PE (1) | PE20120020A1 (fr) |
PL (1) | PL2389164T3 (fr) |
RU (1) | RU2489153C2 (fr) |
SG (1) | SG173001A1 (fr) |
SI (1) | SI2389164T1 (fr) |
TW (1) | TWI414295B (fr) |
UA (1) | UA100937C2 (fr) |
WO (1) | WO2010084041A2 (fr) |
ZA (1) | ZA201104882B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012062691A1 (fr) * | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Compositions pharmaceutiques pour le traitement des infections par le virus de l'hépatite c |
CN105050708A (zh) | 2012-11-14 | 2015-11-11 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
DE102013215831A1 (de) * | 2013-08-09 | 2015-02-12 | Beiersdorf Ag | Gelförmiges, alkoholisches Sonnenschutzmittel |
WO2016121925A1 (fr) * | 2015-01-30 | 2016-08-04 | 協和発酵バイオ株式会社 | Comprimé contenant une proportion élevée de substance fonctionnelle et procédé de fabrication dudit comprimé |
WO2017140253A1 (fr) * | 2016-02-19 | 2017-08-24 | 江苏恒瑞医药股份有限公司 | Composition pharmaceutique contenant un dérivé d'imidazoline |
JP6323846B2 (ja) * | 2016-04-07 | 2018-05-16 | 塩野義製薬株式会社 | オピオイドを含有する乱用防止製剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0400726A3 (en) * | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
JP4408340B2 (ja) * | 2002-03-22 | 2010-02-03 | 武田薬品工業株式会社 | 速崩壊性固形製剤 |
TWI332507B (en) * | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
KR20080027783A (ko) * | 2005-06-22 | 2008-03-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 난용성 활성 성분을 함유하는 정제 |
JP2008230967A (ja) * | 2005-06-23 | 2008-10-02 | Kowa Co | 医薬組成物 |
NZ568909A (en) * | 2005-12-09 | 2011-10-28 | Hoffmann La Roche | Antiviral 4-fluoro-4-methyl nucleoside prodrugs |
BRPI0619890A2 (pt) * | 2005-12-14 | 2011-10-25 | Hoffmann La Roche | composição farmacêutica e processo para preparação de uma suspensão sólida |
-
2010
- 2010-01-11 AU AU2010206224A patent/AU2010206224B2/en not_active Ceased
- 2010-01-11 UA UAA201110008A patent/UA100937C2/uk unknown
- 2010-01-11 PL PL10700233T patent/PL2389164T3/pl unknown
- 2010-01-11 SG SG2011051240A patent/SG173001A1/en unknown
- 2010-01-11 EP EP10700233.9A patent/EP2389164B1/fr active Active
- 2010-01-11 SI SI201030785T patent/SI2389164T1/sl unknown
- 2010-01-11 PE PE2011001307A patent/PE20120020A1/es not_active Application Discontinuation
- 2010-01-11 JP JP2011546733A patent/JP5415561B2/ja not_active Expired - Fee Related
- 2010-01-11 WO PCT/EP2010/050182 patent/WO2010084041A2/fr active Application Filing
- 2010-01-11 NZ NZ593795A patent/NZ593795A/xx not_active IP Right Cessation
- 2010-01-11 MA MA34019A patent/MA32969B1/fr unknown
- 2010-01-11 MX MX2011007771A patent/MX2011007771A/es active IP Right Grant
- 2010-01-11 KR KR1020117019277A patent/KR101331723B1/ko not_active IP Right Cessation
- 2010-01-11 BR BRPI1006924A patent/BRPI1006924A2/pt not_active IP Right Cessation
- 2010-01-11 CN CN2010800050195A patent/CN102292075B/zh not_active Expired - Fee Related
- 2010-01-11 CA CA2748895A patent/CA2748895C/fr not_active Expired - Fee Related
- 2010-01-11 DK DK10700233.9T patent/DK2389164T3/da active
- 2010-01-11 RU RU2011134713/15A patent/RU2489153C2/ru not_active IP Right Cessation
- 2010-01-11 ES ES10700233.9T patent/ES2513415T3/es active Active
- 2010-01-18 US US12/689,004 patent/US8222230B2/en not_active Expired - Fee Related
- 2010-01-18 TW TW099101246A patent/TWI414295B/zh not_active IP Right Cessation
- 2010-01-20 AR ARP100100124A patent/AR075037A1/es unknown
-
2011
- 2011-06-28 IL IL213804A patent/IL213804A0/en unknown
- 2011-06-30 CO CO11082167A patent/CO6440558A2/es not_active Application Discontinuation
- 2011-07-01 ZA ZA2011/04882A patent/ZA201104882B/en unknown
- 2011-07-07 EC EC2011011191A patent/ECSP11011191A/es unknown
- 2011-07-21 CL CL2011001764A patent/CL2011001764A1/es unknown
-
2012
- 2012-06-12 HK HK12105721.1A patent/HK1164742A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32969B1 (fr) | Compositions pharmaceutiques presentant de remarquables performances et entrainant une excellente adhesion du patient a son traitement | |
EA201170289A1 (ru) | Фармацевтические композиции и способы их получения при низкой концентрации примесей | |
PH12015500301B1 (en) | A novel formulation of diclofenac | |
MA33044B1 (fr) | Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient | |
EA201171279A1 (ru) | Производство инкапсулированных наночастиц с высокой объемной долей | |
GEP20156366B (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
MA34169B1 (fr) | Dérivés d'acide 1-amino-2-cyclopropyléthylboronique | |
PH12016500746A1 (en) | A novel formulation of meloxicam | |
PE20011268A1 (es) | Composiciones farmaceuticas que comprenden una dispersion de solidos amorfos de [(1s)-bencil-(2r)-hidroxi-3-((3r,4s)-dihidroxi-pirrolidin-1-il)-3-oxipropil]amida del acido 5-cloro-1h-indol-2-carboxilico en un polimero que aumenta la concentracion com | |
EA201291168A1 (ru) | Фармацевтические композиции и способы их получения | |
EA201390409A1 (ru) | Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием | |
EA201171281A1 (ru) | Производство инкапсулированных наночастиц в коммерческих масшатабах | |
EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
MX2011011233A (es) | Una formulacion novedosa de metaxalona. | |
MY159208A (en) | A novel formulation of indomethacin | |
EA201200185A1 (ru) | Фармацевтическая композиция для пероральной доставки дииндолилметана | |
EA201171088A1 (ru) | Лечение дискинезии при различных расстройствах | |
CU24523B1 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
RU2014149700A (ru) | Композиции для доставки активных ингредиентов | |
EA201991341A1 (ru) | Фенитоин для местного применения для лечения периферической нейропатической боли | |
RU2013157933A (ru) | Композиции, включающие антибактериальное средство и тазобактам | |
EA201170583A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии | |
MA33512B1 (fr) | Inhibiteurs de la cathepsine c | |
MA38974A1 (fr) | Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate | |
RU2008132536A (ru) | Фармацевтические композиции, содержащие метаксалон |